Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis in Intraocular Pressure (IOP) After Bevacizumab
|ClinicalTrials.gov Identifier: NCT00804921|
Recruitment Status : Completed
First Posted : December 9, 2008
Last Update Posted : December 9, 2008
Purpose: To evaluate the effects of anterior chamber paracentesis, brimonidine and oral acetazolamide to reduce intra-ocular pressure (IOP) variations after intravitreal bevacizumab injection (IVBV).
Methods: 47 patients scheduled for IVBV (1.5 mg / 0.06 ml) will be randomly assigned to a pre-treatment 1 hour before IVBV with either 250 mg oral acetazolamide (DIA, 9 eyes), anterior chamber paracentesis immediate after IVBV (PAR, 15 eyes), topic brimonidine tartarate 1 hour before IVBV (BRI, 14 eyes), or no pre-treatment IBVB (CTR, 9 eyes). IOP will be measured 90 minutes before injection (baseline), just before injection, and at 3, 10, 20 and 30 minutes after the procedure.
|Condition or disease||Intervention/treatment||Phase|
|Macular Edema Diabetic Retinopathy Macular Degeneration||Drug: bevacizumab Procedure: anterior chamber paracentesis Drug: acetazolamide Drug: brimonidine||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab Injection: Preliminary Results|
- Intra-ocular pressure variation after intra-vitreous injection of bevacizumab
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00804921
|School of Medicine - Clinical Hospital|
|Ribeirao Preto, SP, Brazil, 14049-900|